{
    "eid": "2-s2.0-85144576230",
    "title": "Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Analytical Chemistry",
            "@code": "1602",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Chemistry (miscellaneous)",
            "@code": "1601",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmaceutical Science",
            "@code": "3003",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Physical and Theoretical Chemistry",
            "@code": "1606",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Organic Chemistry",
            "@code": "1605",
            "@abbrev": "CHEM"
        }
    ],
    "keywords": [
        "EGFR (L858R/T790M/C797S) TK",
        "EGFR tyrosine kinase",
        "in silico drug discovery and development",
        "lung cancer",
        "non-small cell lung cancer"
    ],
    "authors": [
        "Utid Suriya",
        "Panupong Mahalapbutr",
        "Watchara Wimonsong",
        "Sirilata Yotphan",
        "Kiattawee Choowongkomon",
        "Thanyada Rungrotmongkol"
    ],
    "citedby-count": 1,
    "ref-count": 58,
    "ref-list": [
        "EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story",
        "Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors",
        "EGFR antagonists in cancer treatment",
        "The quest to overcome resistance to EGFR-targeted therapies in cancer",
        "Emerging functions of the EGFR in cancer",
        "Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update",
        "Epidermal growth factor-related peptides and their receptors in human malignancies",
        "Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: The need to test neoplasms with more than one method",
        "Mechanisms of resistance to EGFR tyrosine kinase inhibitors",
        "Determinants of tumor response and survival with erlotinib in patients with non\u2014Small-cell lung cancer",
        "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial",
        "Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma",
        "Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR",
        "Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report",
        "Afatinib",
        "Afatinib: First global approval",
        "WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors",
        "Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLCDevelopment of Covalent EGFRT790M Inhibitor in NSCLC",
        "Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: Implications for formulation, dose, and dosing frequency in pivotal clinical studies",
        "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsRAS Pathway Activation and Resistance to EGFR TKIs",
        "Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy",
        "Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: A case report",
        "Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant",
        "Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site",
        "Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors",
        "Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)",
        "Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFRL858R/T790M/C797S)",
        "Discovery of 2, 4, 6-trisubstitued pyrido [3, 4-d] pyrimidine derivatives as new EGFR-TKIs",
        "Structural optimization and structure\u2013activity relationships of N 2-(4-(4-Methylpiperazin-1-yl) phenyl)-N 8-phenyl-9 H-purine-2, 8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations",
        "A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine",
        "Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling",
        "Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities",
        "Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies",
        "AutoDock VinaXB: Implementation of XBSF, new empirical halogen bond scoring function, into AutoDock Vina",
        "Integration of In Silico Strategies for Drug Repositioning towards P38&alpha; Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site",
        "Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR",
        "Ten things you should know about protein kinases: IUPHAR R eview 14",
        "CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation",
        "SWISS-MODEL: Homology modelling of protein structures and complexes",
        "PROCHECK: A program to check the stereochemical quality of protein structures",
        "PIDA-induced oxidative C\u2013N bond coupling of quinoxalinones and azoles",
        "Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors",
        "ADP-Glo: A Bioluminescent and Homogeneous ADP Monitoring Assay for Kinases",
        "Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives",
        "In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach",
        "In Silico Screening of DNA Gyrase B Potent Flavonoids for the Treatment of Clostridium difficile Infection from PhytoHub Database",
        "Development and testing of a general amber force field",
        "Comparison of simple potential functions for simulating liquid water",
        "The investigation of binary and ternary sulfobutylether-\u03b2-cyclodextrin inclusion complexes with asiaticoside in solution and in solid state",
        "Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists",
        "Particle mesh Ewald: An N\u22c5 log (N) method for Ewald sums in large systems",
        "Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes",
        "Synchronization of trajectories in canonical molecular-dynamics simulations: Observation, explanation, and exploitation",
        "Molecular dynamics with coupling to an external bath",
        "SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules",
        "DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis",
        "ProTox-II: A webserver for the prediction of toxicity of chemicals"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60021944",
            "affilname": "Kasetsart University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021944",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "60012718",
            "affilname": "Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012718",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Science Achievement Scholarship",
        "Chulalongkorn University",
        "Khon Kaen University",
        "National Research Council of Thailand",
        "SAST",
        "Kasetsart University Research and Development Institute"
    ]
}